Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed EBT for 14 consecutive years, with -$11.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 47.53% year-over-year to -$11.9 million, compared with a TTM value of -$72.8 million through Dec 2025, up 31.66%, and an annual FY2025 reading of -$83.5 million, up 29.07% over the prior year.
  • EBT was -$11.9 million for Q4 2025 at Enanta Pharmaceuticals, up from -$18.7 million in the prior quarter.
  • Across five years, EBT topped out at -$11.9 million in Q4 2025 and bottomed at -$37.6 million in Q1 2023.
  • Average EBT over 5 years is -$28.1 million, with a median of -$29.4 million recorded in 2023.
  • The sharpest move saw EBT tumbled 193.75% in 2021, then skyrocketed 47.53% in 2025.
  • Year by year, EBT stood at -$30.2 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then decreased by 17.26% to -$34.0 million in 2023, then surged by 33.27% to -$22.7 million in 2024, then surged by 47.53% to -$11.9 million in 2025.
  • Business Quant data shows EBT for ENTA at -$11.9 million in Q4 2025, -$18.7 million in Q3 2025, and -$18.2 million in Q2 2025.